Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes

Yilmaz-Aydogan, Hülya; Kurnaz, Ozlem; Küçükhüseyin, Özlem; Akadam-Teker, Başak; Kurt, Özlem Kar; Eronat, Allison Pinar; Tekeli, Atike; Buğra, Zehra; Öztürk, Oğuz

doi:10.1016/j.gene.2013.03.136

Cited by 21 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…"Ala12Ala" and "TT" genotypes were not observed in the control group (0%) whereas the frequencies of them were 1.2% and 3% in the patient group, respectively. The genotype populations of PPARγ Pro12Ala/C161T were in accordance with those in Turkish patients with inflammatory bowel disease, coronary heart disease and gastric cancer (Atug et al 2008;Yilmaz-Aydogan et al 2011;Canbay et al 2012). Similar to our results, Erdogan et al (2007) reported the frequency as 0% for "Ala12Ala" genotype in the control group and in diabetic patients with and without diabetic nefropathy.…”

Section: Discussionsupporting

confidence: 66%

See 1 more Smart Citation

PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women

Şirin¹,

Yilmaz-Aydogan²,

Uyar³

et al. 2019

Istanbul J Pharm

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptors (PPARs) belong to the superfamily of nuclear receptors which are are ligand-activated transcription factors. Three different PPAR subtypes have been identified; PPARα, PPARβ (also called PPARδ), and PPARγ (Abbot 2009). PPARα is found in tissues such as heart, muscle, liver and kidney where fatty acid catabolism is important and so regulates genes involved in lipid metabolism. PPARα is activated by natural ligands (polyunsaturated fatty acids, lipolytic products of lipoproteins, oxidized phospholipids) and by synthetic ligands (gemfibrozil and fenofibrate) (Touyz and Schiffrin 2006). Fenofibrate which is currently used for the treatment of hypercholesterolemia and hypertriglyceridemia, also maintains bone mass. Whole body and femoral bone mineral density (BMD) values were higher in ovariectomized rats given fenofibrate, compared to controls (Stunes et al. 2011).PPARγ is heavily expressed in adipose tissue and controls adipocyte differentiation and lipid storage. PPARγ regulates the action of insulin through its effects on adipose tissue and skeletal muscle (Touyz and Schiffrin 2006). Natural agonists (eicosanoids and oxidized, polyunsaturated fatty acids) and synthetic agonists (thiazolidinediones; a family of antidiabetic drugs-rosiglitazone and

show abstract

Section: Discussionsupporting

confidence: 66%

“…Genomic DNA samples were extracted from whole blood with salting out procedure (Miller et al 1988). Polymerase chain reaction-restriction fragment lenght polymorphism (PCR-RFLP) analysis were used to detect PPARα L162V and PPARγ Pro12Ala/ C161T polymorphisms as previously reported (Yen et al 1997;Flavell et al 2002).…”

Section: Genotype Studymentioning

confidence: 99%

PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women

Şirin¹,

Yilmaz-Aydogan²,

Uyar³

et al. 2019

Istanbul J Pharm

View full text Add to dashboard Cite

show abstract

“…For instance, some studies have reported that carriers of the T allele of His447His (rs3856806) have increased obesity risk [23], poor lipid profile [28–30], and risk of metabolic syndrome [27] and coronary heart diseases (CHD) [9]. On the other hand, others have failed to demonstrate an association between PPARG SNPs including C161T with CHD susceptibility [31], whilst some have shown increased insulin sensitivity [10, 26], decreased CHD, body mass index, and diabetes risk [25, 26, 29, 32] in subjects harbouring the T allele. In our study, presence of the T allele was associated with reducing the risk of prevalent diabetes and levels of insulin resistance indices.…”

Section: Discussionmentioning

confidence: 99%

Rare Mutations of Peroxisome Proliferator-Activated Receptor Gamma: Frequencies and Relationship with Insulin Resistance and Diabetes Risk in the Mixed Ancestry Population from South Africa

Vergotine

Kengne

Erasmus

et al. 2014

International Journal of Endocrinology

View full text Add to dashboard Cite

Background. Genetic variants in the nuclear transcription receptor, PPARG, are associated with cardiometabolic traits, but reports remain conflicting. We determined the frequency and the clinical relevance of PPARG SNPs in an African mixed ancestry population. Methods. In a cross-sectional study, 820 participants were genotyped for rs1800571, rs72551362, rs72551363, rs72551364, and rs3856806, using allele-specific TaqMan technology. The homeostatic model assessment of insulin (HOMA-IR), β-cells function (HOMA-B%), fasting insulin resistance index (FIRI), and the quantitative insulin-sensitivity check index (QUICKI) were calculated. Results. No sequence variants were found except for the rs3856806. The frequency of the PPARG-His447His variant was 23.8% in the overall population group, with no difference by diabetes status (P = 0.215). The His447His allele T was associated with none of the markers of insulin resistance overall and by diabetes status. In models adjusted for 2-hour insulin, the T allele was associated with lower prevalent diabetes risk (odds ratio 0.56 (95% CI 0.31–0.95)). Conclusion. Our study confirms the almost zero occurrences of known rare PPARG SNPs and has shown for the first time in an African population that one of the common SNPs, His447His, may be protective against type 2 diabetes.

show abstract

“…Moreover, PPARα V162 allele increases total cholesterol and LDL-cholesterol levels. This effect was reduced by carrying the PPARγ T161 allele in patients with non-diabetic coronary heart disease (CHD) [45]. Another polymorphism associated with CHD is C161T in patients with T2D.…”

Section: Human Aspects Of Pparγ In Metabolic Syndromementioning

confidence: 99%

Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?

Pap

Cuaranta-Monroy

Peloquin

et al. 2016

IJMS

View full text Add to dashboard Cite

With the increasing number of patients affected with metabolic diseases such as type 2 diabetes, obesity, atherosclerosis and insulin resistance, academic researchers and pharmaceutical companies are eager to better understand metabolic syndrome and develop new drugs for its treatment. Many studies have focused on the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ), which plays a crucial role in adipogenesis and lipid metabolism. These studies have been able to connect this transcription factor to several human metabolic diseases. Due to obvious limitations concerning experimentation in humans, animal models—mainly mouse models—have been generated to investigate the role of PPARγ in different tissues. This review focuses on the metabolic features of human and mouse PPARγ-related diseases and the utility of the mouse as a model.

show abstract

Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes

Cited by 21 publications

References 29 publications

PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women

PPARγ Pro12Ala and C161T polymorphisms, but not PPARα L162V, are associated with osteoporosis risk in Turkish postmenopausal women

Rare Mutations of Peroxisome Proliferator-Activated Receptor Gamma: Frequencies and Relationship with Insulin Resistance and Diabetes Risk in the Mixed Ancestry Population from South Africa

Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?

Contact Info

Product

Resources

About